Recent Updates
Recently added Catalysts

323U66

Phase 3

Depressive Disorder | Small molecule | Other |GSK plc|Last Updated: Dec 4, 2019

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment325
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00296517Study In Patients With Depression Not Responding to Selective Serotonin Re-uptake InhibitorsPHASE3 COMPLETED 325Jan 19, 2006Mar 28, 2008Dec 4, 201962 Japan
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Change From Baseline in the Hamilton Depression Scale (HAM-D 17 Items) Total Score
Baseline and Week 12

The Hamilton Rating Scale for Depression contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAM-D score range from 0 (not ill) to 52 (severely ill).

Secondary Endpoints
Hamilton Depression Scale (HAM-D 17 Items) Total Score
Week 8 and Week 12
Change From Baseline in the Hamilton Depression Scale (HAM-D 17 Items) Total Score at Week 8 and Total Score at Week 12
Baseline to Week 8 and Week 12
Percentage of Change From Baseline of the Hamilton Depression (HAM-D 17 Items) Total Score at Weeks 8 and 12.
Baseline to Week 8 and Week 12
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
PlaceboPLACEBO_COMPARATORSubjects with Major Depressive Disorder who were randomised to placebo to match Bupropion SR during the treatment period.
Bupropion SREXPERIMENTALSubjects with Major Depressive Disorder who were randomized to take 100mg of Bupropion SR in the morning and placebo in the evening for one week. Week 2 subjects were given 100mg dose of Bupropion morning and evening. Weeks 3 thru 12 received 150mg dose morning and evening. Week 1=dose level 1, 100 mg. Week 2=dose level 2, 200 mg. Weeks 3 - 12=dose level 3, 300 mg.
Interventions
NameTypeDescription
323U66 (Bupropion Hydrochloride Sustained Release)DRUGSubjects with Major Depressive Disorder who were randomized to take 100mg of Bupropion SR in the morning and placebo in the evening for one week. Week 2 subjects were given 100mg dose of Bupropion morning and evening. Weeks 3 thru 12 received 150mg dose morning and evening. Week 1=dose level 1, 100 mg. Week 2=dose level 2, 200 mg. Weeks 3 - 12=dose level 3, 300 mg.
PlaceboDRUGSubjects with Major Depressive Disorder who were randomised to placebo to match Bupropion SR during the treatment period.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 65 Years
SexALL
Healthy VolunteersNo
Study Sites62

Inclusion criteria: * \[At the start of the pretreatment phase\] * Target disease: Patients diagnosed as having the following primary disease on the basis of DSM-IV-TR criteria. * Major Depressive Disorder, Single Episode (296.2x) (excluding with psychotic features) * Major Depressive Disorder, Rec...

Countries:Japan
Unlock Eligibility Criteria